Author Archives: Iqra Mumal, MSc

Health Canada Approves Mayzent to Treat Active SPMS

Health Canada has approved Novartis‘s Mayzent (siponimod) for the treatment of adults with active secondary progressive multiple sclerosis (SPMS) to delay the progression of physical disability. Active disease is determined either by the presence of relapses or magnetic resonance imaging features characteristic of inflammatory activity. Multiple sclerosis (MS)…

NeurologyLive, CMSC Offer Panel Series on Changes in MRI Guidelines for MS

NeurologyLive, a multimedia platform for specialists in that field, partnered with the Consortium of Multiple Sclerosis Centers (CMSC) for its recent video series on changes in magnetic resonance imaging (MRI) protocol and guidelines for treating and managing multiple sclerosis (MS). This “Peer Exchange” panel discussion includes four specialists in neurology…

CMSC Announces 4 Winners of Pilot Research Awards for 2019

The Consortium of Multiple Sclerosis Centers (CMSC) named four scientists the winners of its Pilot Research Award for 2019, given to support projects thought to advance the CMSC’s mission and improve the lives of people with multiple sclerosis (MS). The awards, supported by EMD Serono (known as Merck…

Tysabri Treatment Leads to Disease Activity-free Status in Patients with Pediatric-onset MS

Early treatment with Tysabri (natalizumab) of patients with aggressive pediatric-onset multiple sclerosis is highly effective at achieving disease activity-free status and preventing cognitive decline, a new study shows. The study, “No evidence of disease activity including cognition (NEDA-3 plus) in naïve pediatric multiple sclerosis patients treated with natalizumab,”…

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These flash briefings give our readers an alternative option for accessing information important for them.

Listen Here

Video